Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Downgrades Forma Therapeutics Hldgs to Perform

Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.

byBenzinga Newsdesk

September 2, 2022

1 minute read

Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.

BMO Capital Upgrades BRP to Outperform, Raises Price Target to C$154

By vishwanath@benzinga.com

September 7, 9:59 AM

BMO Capital analyst Gerrick Johnson upgrades BRP (NASDAQ:DOOO) from Market Perform to Outperform and raises the price target from C$100 to C$154.

DOOO

Credit Suisse Maintains Outperform on Angi, Lowers Price Target to $10

By Benzinga Newsdesk

August 11, 10:27 AM

Credit Suisse analyst Stephen Ju maintains Angi (NASDAQ:ANGI) with a Outperform and lowers the price target from $12 to $10.

ANGI

SCWorx Announces Renewal And Expansion Of Existing Contract With A New England Hospital; New Agreement Is For Four Years And $200K/Year

By Bill Haddad

August 30, 10:02 AM

SCWorx Corp (NASDAQ:WORX) today announced the renewal and expansion of a data service agreement with an existing 500+ bed hospital in New England. The healthcare provider was previously under a 1

WORX

Equinor On April 20 Reported Output Began At Roncador Project With Petrobras

By Benzinga Newsdesk

April 26, 10:54 AM

https://www.zacks.com/stock/news/1907670/petrobras-pbr-equinor-begin-output-at-roncador-project

EQNR

Oppenheimer Downgrades Forma Therapeutics Hldgs to Perform

Related Posts

BMO Capital Upgrades BRP to Outperform, Raises Price Target to C$154

Credit Suisse Maintains Outperform on Angi, Lowers Price Target to $10

SCWorx Announces Renewal And Expansion Of Existing Contract With A New England Hospital; New Agreement Is For Four Years And $200K/Year

Equinor On April 20 Reported Output Began At Roncador Project With Petrobras